复星医药 reported revenue of ¥20.44B for the period ended 2026-06-30, +4.8% year on year. Net income was ¥2.15B, a 10.5% net margin on a 49.7% gross margin. The largest revenue line is 制药 at 72% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥20.44B | +4.8% |
| Gross profit | ¥10.15B | — |
| Operating income | ¥2.62B | — |
| Net income | ¥2.15B | +2.3% |
| Gross margin | 49.7% | Net margin 10.5% |
| Revenue Q/Q | +2.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 制药 | ¥14.79B | 72.3% |
| 医疗健康服务 | ¥3.74B | 18.3% |
| 医疗器械与医学诊断 | ¥1.86B | 9.1% |
| 其他 | ¥0.06B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥10.29B | 50.3% |
| R&D | ¥2.09B | 10.2% |
| SG&A | ¥6.62B | 32.4% |
| Tax & other | ¥0.47B | 2.3% |
| Item | Amount |
|---|---|
| Total assets | ¥125.43B |
| Total liabilities | ¥62.03B |
| Shareholders' equity | ¥63.40B |
| Equity / assets | 50.5% |
| Operating cash flow | ¥1.28B |
| Capital expenditure | ¥1.34B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | 113% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
南山铝业 ・ 海航控股 ・ 圆通速递 ・ 恒瑞医药 ・ 万华化学 ・ 恒力石化 ・ 江西铜业 ・ 中航机载 ・ 国电南瑞 ・ 小商品城 ・ 华鲁恒升 ・ 片仔癀
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies